Coppell Advisory Solutions LLC Acquires New Shares in Protagonist Therapeutics, Inc. $PTGX

Key Points

• Coppell Advisory Solutions LLC has acquired a new stake in Protagonist Therapeutics, purchasing 20,765 shares valued at approximately $947,000 in the first quarter.
• Protagonist Therapeutics' stock has a consensus rating of "Buy" and an average price target of $67.20 according to multiple analysts.
• Insiders have recently sold a total of 66,859 shares, representing a decrease in their holdings of the company, while insiders still own 4.90% of the company's stock.

Coppell Advisory Solutions LLC acquired a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 20,765 shares of the company's stock, valued at approximately $947,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. GF Fund Management CO. LTD. raised its holdings in shares of Protagonist Therapeutics by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 1,526 shares of the company's stock valued at $74,000 after buying an additional 275 shares during the period. Hsbc Holdings PLC raised its holdings in shares of Protagonist Therapeutics by 4.1% during the 1st quarter. Hsbc Holdings PLC now owns 8,458 shares of the company's stock valued at $405,000 after buying an additional 330 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Protagonist Therapeutics by 0.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company's stock valued at $1,810,000 after buying an additional 348 shares during the period. Covestor Ltd raised its holdings in shares of Protagonist Therapeutics by 27.0% during the 1st quarter. Covestor Ltd now owns 2,087 shares of the company's stock valued at $101,000 after buying an additional 444 shares during the period. Finally, AlphaQuest LLC raised its holdings in shares of Protagonist Therapeutics by 24.2% during the 1st quarter. AlphaQuest LLC now owns 2,704 shares of the company's stock valued at $131,000 after buying an additional 527 shares during the period. 98.63% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director William D. Waddill sold 4,000 shares of the business's stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $59.25, for a total value of $237,000.00. Following the completion of the sale, the director directly owned 9,130 shares in the company, valued at approximately $540,952.50. The trade was a 30.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Dinesh V. Ph D. Patel sold 10,415 shares of the business's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $54.78, for a total value of $570,533.70. Following the completion of the sale, the chief executive officer owned 520,603 shares of the company's stock, valued at $28,518,632.34. This trade represents a 1.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 66,859 shares of company stock valued at $3,687,577 over the last quarter. Company insiders own 4.90% of the company's stock.

Protagonist Therapeutics Trading Down 1.4%

PTGX stock traded down $0.82 during midday trading on Friday, hitting $58.86. 685,841 shares of the company's stock were exchanged, compared to its average volume of 880,496. Protagonist Therapeutics, Inc. has a 12-month low of $33.31 and a 12-month high of $61.89. The firm has a 50 day moving average price of $55.70 and a 200-day moving average price of $50.87. The stock has a market capitalization of $3.66 billion, a price-to-earnings ratio of 84.09 and a beta of 2.22.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.02). Protagonist Therapeutics had a return on equity of 8.12% and a net margin of 24.88%.The business had revenue of $5.55 million for the quarter, compared to analysts' expectations of $8.32 million. On average, sell-side analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Protagonist Therapeutics in a report on Tuesday, June 3rd. JMP Securities raised their target price on Protagonist Therapeutics from $67.00 to $69.00 and gave the company a "market outperform" rating in a report on Thursday, August 7th. Leerink Partners assumed coverage on Protagonist Therapeutics in a report on Friday. They set an "outperform" rating and a $73.00 target price on the stock. Wall Street Zen upgraded Protagonist Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, June 8th. Finally, Leerink Partnrs upgraded Protagonist Therapeutics to a "strong-buy" rating in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $67.73.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.